Literature DB >> 2875254

Cerebrospinal fluid inflammation during OKT3 therapy.

C Emmons, J Smith, M Flanigan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 2875254     DOI： 10.1016/s0140-6736(86)90375-2

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  5 in total

Review 1.  The role of OKT3 in clinical transplantation.

Authors:  D J Norman; M R Leone
Journal:  Pediatr Nephrol       Date:  1991-01       Impact factor: 3.714

Review 2.  Drug-induced aseptic meningitis: diagnosis and management.

Authors:  S Jolles; W A Sewell; C Leighton
Journal:  Drug Saf       Date:  2000-03       Impact factor: 5.606

Review 3.  Muromonab CD3. A review of its pharmacology and therapeutic potential.

Authors:  P A Todd; R N Brogden
Journal:  Drugs       Date:  1989-06       Impact factor: 9.546

4.  Treatment of Guillain-Barré syndrome with anti-T cell monoclonal antibodies.

Authors:  T E Feasby
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-01       Impact factor: 10.154

Review 5.  Prevention and management of the adverse effects associated with immunosuppressive therapy.

Authors:  S J Rossi; T J Schroeder; S Hariharan; M R First
Journal:  Drug Saf       Date:  1993-08       Impact factor: 5.606
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.